Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins

Current Cardiology Reports
Abeer AnabtawiJohn M Miles

Abstract

The purpose of the study is to review the use of statins and the role of both non-statin lipid-lowering agents and diabetes-specific medications in the treatment of diabetic dyslipidemia. Statins have a primary role in the treatment of dyslipidemia in people with type 2 diabetes, defined as triglyceride levels >200 mg/dl and HDL cholesterol levels <40 mg/dL. A number of clinical trials suggest that treatment with a fibrate may reduce cardiovascular events. However, the results of these trials are inconsistent, probably because many of their participants did not have dyslipidemia. The choice of medications used to treat diabetes can have major implications regarding management of dyslipidemia; metformin, GLP-1 agonists, and pioglitazone all have favorable lipid effects. These agents, as well as the new SGLT2 inhibitors, may reduce cardiovascular events. Management of dyslipidemia in people with type 2 diabetes should start with statin therapy and optimal glycemic control with agents that have favorable lipid and cardiovascular effects. We believe that there is a role for adding fenofibrate to moderate-intensity statins in selected patients with true dyslipidemia. We propose an algorithm for selecting add-on medications for diabe...Continue Reading

References

Dec 1, 1992·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·K R FeingoldR M Krauss
Dec 17, 1997·The Journal of Clinical Endocrinology and Metabolism·H Yki-JärvinenM R Taskinen
Jul 24, 1998·Journal of Cardiovascular Pharmacology·N M GenevD K Yue
Jun 5, 1999·The American Journal of Cardiology·S M Grundy
Jul 6, 2000·Circulation·UNKNOWN Bezafibrate Infarction Prevention (BIP) study
Apr 13, 2001·JAMA : the Journal of the American Medical Association·S J RobinsUNKNOWN VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial
Jul 20, 2001·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·M R Taskinen
May 9, 2002·Atherosclerosis·Isabelle LemieuxJean Pierre Després
Jan 10, 2003·The Journal of Clinical Endocrinology and Metabolism·Sonia ArunabhJohn F Aloia
Apr 30, 2003·Diabetes·Charles M AlexanderUNKNOWN National Cholesterol Education Program (NCEP)
Nov 5, 2003·Expert Opinion on Pharmacotherapy·Harold Bays, Evan A Stein
Mar 5, 2004·JAMA : the Journal of the American Medical Association·Steven E NissenUNKNOWN REVERSAL Investigators
Mar 10, 2004·The New England Journal of Medicine·Christopher P CannonUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
Jun 3, 2004·Journal of the American College of Cardiology·James H O'KeefeRobert Vogel
Feb 8, 2005·The American Journal of Cardiology·Scott M GrundyJoanne Palmisano
Mar 9, 2005·Endocrinology and Metabolism Clinics of North America·Maria Del Pilar Solano, Ronald B Goldberg
Oct 4, 2005·Journal of the American College of Cardiology·Peter Libby
Nov 18, 2005·The Journal of Clinical Endocrinology and Metabolism·Henry N Ginsberg
Feb 3, 2006·Cardiovascular Drugs and Therapy·Eric BruckertBernard Bégaud
Apr 4, 2006·The American Journal of Cardiology·Terry A Jacobson
Jun 27, 2006·Clinical Cardiology·Michael H DavidsonUNKNOWN TRIMS Investigators
Aug 19, 2007·Diabetes, Obesity & Metabolism·D John Betteridge
Feb 21, 2008·The Annals of Pharmacotherapy·James M BackesPatrick M Moriarty
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Aug 13, 2010·The New England Journal of Medicine·Christoph H SaelyHeinz Drexel
Sep 17, 2010·The New England Journal of Medicine·William J Perkins
Nov 17, 2011·The New England Journal of Medicine·William E BodenWilliam Weintraub

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.